Faustine T.
- Country
- France
- Department
- pediatric oncology
Research Overview
- Randomized Phase II/III Study of Cabozantinib Maintenance Versus Best Supportive Care in Osteosarcoma Patients After First‑Line Chemotherapy (FOSTER‑CabOS)
- Evaluation of Regorafenib Addition to VDC/IE Chemotherapy and Maintenance Vinorelbine-Cyclophosphamide in Newly Diagnosed Metastatic Ewing Sarcoma
- Randomized, Double-Blind, Placebo-Controlled Study of Regorafenib as Maintenance Therapy in Patients with Bone Sarcomas Post First-Line Treatment
Data & Insights
Has run more than one trial at 33 of 98 partner sites.
Specializations
Bone Cancer Specialization
The investigator specializes in treating and researching high-grade bone sarcomas, focusing particularly on cases both at initial diagnosis and relapse stages.
- Primary bone malignancies
- Treatment-resistant sarcomas
- Maintenance therapy approaches
Their expertise extends to managing patients with residual disease following standard treatment protocols.
Therapeutic Innovation
The investigator focuses on developing maintenance treatment strategies for bone cancer patients, particularly exploring novel therapeutic approaches for cases without complete remission.
- Advanced treatment protocols
- Post-standard therapy care
- Disease management strategies
Their work encompasses various bone sarcoma subtypes, excluding chordoma, with emphasis on innovative therapeutic solutions.
Treatment Outcomes
The investigator's work centers on evaluating therapeutic efficacy in bone sarcoma treatments, particularly focusing on maintenance therapy outcomes in various patient populations.
- Response assessment
- Long-term disease control
- Treatment effectiveness monitoring
Their research includes comparative analysis of treatment outcomes in different bone sarcoma presentations.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.